Provided by Tiger Fintech (Singapore) Pte. Ltd.

BeiGene

184.71
+0.0000
Volume:- -
Turnover:61.43M
Market Cap:19.67B
PE:-22.56
High:184.71
Open:184.71
Low:184.71
Close:184.71
Loading ...

BeiGene Secures FDA Approval for Stomach Cancer Drug

MT Newswires
·
27 Dec 2024

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Markets Sluggishly Move to Year-End

MT Newswires Live
·
27 Dec 2024

BeiGene Gets FDA Approval for Tevimbra in Stomach-Esophagus Junction Cancer

MT Newswires Live
·
27 Dec 2024

BeiGene Stomach-Cancer Treatment Gets FDA Approval, Second in U.S.

Dow Jones
·
27 Dec 2024

BeiGene announces FDA approval of Tevimbra

TIPRANKS
·
27 Dec 2024

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.
·
24 Dec 2024

With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns

Simply Wall St.
·
24 Dec 2024

BeiGene Ltd Updates Nasdaq Ticker Symbol

TIPRANKS
·
23 Dec 2024

BeiGene to Change Ticker Symbol to 'ONC', Reflecting Oncology Commitment

MT Newswires Live
·
23 Dec 2024

BRIEF-Beigene's Nasdaq Stock Code To Be Changed

Reuters
·
23 Dec 2024

BeiGene to change ticker symbol to ‘ONC’ on January 2, 2025

TIPRANKS
·
23 Dec 2024

BeiGene gets FDA orphan designation in Waldenstrom macroglobulinemia treatment

TIPRANKS
·
19 Dec 2024

BeiGene’s Strategic Advancements and Promising Clinical Developments Justify Buy Rating

TIPRANKS
·
18 Dec 2024

BeiGene’s Strategic Advancements and Promising Pipeline Drive Buy Rating

TIPRANKS
·
17 Dec 2024

BeiGene (BGNE) Gets a Buy from TD Cowen

TIPRANKS
·
17 Dec 2024

BeiGene, Ltd.'s (NASDAQ:BGNE) recent 15% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.
·
17 Dec 2024

BeiGene: Promising Growth Trajectory and Investment Opportunity Backed by Strong Product Pipeline and Robust Financials

TIPRANKS
·
17 Dec 2024

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires Live
·
13 Dec 2024